**Supplementary Table 9.** **Prediction results of each cancer type using 262 CpG markers measured by bsCUP-seq in 100 clinical samples.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cancer type** | **Number of cases** | **Correct top-rank** | **Correct 2nd rank** | **Incorrect** |
| BLCA | 5 | 5 | 0 | 0 |
| BRCA | 10 | 8 | 1 (LUAD) | 1 (LUAD) |
| CESC | 6 | 5 | 1 (LUAD) | 0 |
| CHOL | 5 | 0 | 2 (1 LUAD, 1 CESC) | 3 (1 CRAD, 1 LUAD, 1 LUSC) |
| CRAD | 10 | 9 | 0 | 1 (ESST) |
| ESST | 9 | 6 | 1 (MESO) | 2 (1 ACC, 1 LUAD) |
| KIPAN | 12 | 11 | 1 (LUAD) | 0 |
| LIHC | 10 | 6 | 4 (4 CHOL) | 0 |
| LUAD | 4 | 3 | 0 | 1 (ESST) |
| LUSC | 2 | 1 | 0 | 1 (ESST) |
| MESO | 1 | 1 | 0 | 0 |
| OV | 7 | 5 (3 OV, 2 UCEC) | 0 | 2 (1 CESC, 1 SKCM) |
| PAAD | 7 | 0 | 1 (CHOL) | 6 (2 SKCM, 1 BRCA, 1 CESC, 1 ESST, 1 LUAD) |
| PRAD | 1 | 1 | 0 | 0 |
| SKCM | 1 | 1 | 0 | 0 |
| THCA | 4 | 4 | 0 | 0 |
| UCEC | 6 | 4 | 0 | 2 (2 CESC) |
| Total | 100 | 70 (70%) | 11 (11%) | 19 (19%) |

\*bracket: top-ranked tumor of each sample. Abbreviations: BLCA: bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical and endocervical carcinoma; CHOL, cholangiocarcinoma; CRAD, colorectal adenocarcinoma; ESST, esophageal and gastric adenocarcinoma; KIPAN, kidney renal cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovary serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; SKCM, skin cutaneous melanoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma.